Krishna Institute of Medical Sciences Limited has announced completion of postal ballot notice dispatch for a qualified institutions placement (QIP) to raise funds up to Rs 1500 crores. The company published newspaper advertisements on March 17, 2026, confirming the completion of notice dispatch to all eligible shareholders for the special resolution on equity share issuance.

Newspaper Advertisement and Regulatory Compliance

The company published the postal ballot notice in Financial Express (English) and Navatelangana (Telugu) newspapers pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisement confirms completion of notice dispatch through email to all shareholders who registered their email IDs as of the cut-off date.

The notice is accessible on the company's website at www.kimshospitals.com under the investors section, as well as on BSE and NSE websites for transparency and regulatory compliance.

Proposed QIP Structure and Compliance Framework

The special resolution seeks approval for issuing equity shares through QIP in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The proposed issuance maintains strict regulatory compliance:

• Allotment exclusively to Qualified Institutional Buyers (QIBs)
• Completion within 365 days from resolution approval
• Pricing not less than floor price per SEBI regulations, with maximum 5% discount permitted
• No single allottee to receive more than 50% of QIP size
• Minimum 10% allocation to mutual funds
• One-year lock-in period for allotted shares

Mr. Krishna Rao Inturi of IKR & Associates serves as the scrutinizer for the postal ballot process, with Link Intime India Private Limited providing e-voting services through their platform.

Fund Utilization and Strategic Objectives

The Board of Directors approved the fundraising proposal on March 11, 2026, with proceeds intended for multiple strategic purposes:

The resolution provides the Board with flexibility to determine the exact structure, timing, and pricing of the issuance in consultation with lead managers and advisors, considering prevailing market conditions.

Voting Process and Shareholder Services

Shareholders can access e-voting services through Link Intime India Private Limited's platform at instavote.linkintime.co.in. For grievances or queries, shareholders can contact enotices@linkintime.co.in or call +91 22 4918 6000. The company's compliance officer, Ms. Nagajayanthi J.R, is available at cs@kimshospitals.com for additional support.

Results will be announced by the Chairman & Managing Director within two working days from e-voting closure and communicated to BSE and NSE. The QIP will be conducted under SEBI-registered credit rating agency monitoring through quarterly reports until complete fund deployment.

Krishna Institute of Medical Sciences Limited has announced a scheduled analyst and institutional investor meeting as part of the DAM Capital Hospitals & Diagnostics conference. The meeting represents part of the company's ongoing investor engagement activities in compliance with regulatory requirements.

Meeting Details

The healthcare provider has disclosed the following details for the upcoming investor interaction:

Regulatory Compliance

The announcement has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to disclose material events and information that could impact investor decisions.

Krishna Institute of Medical Sciences has specifically stated that no unpublished price sensitive information will be shared during the meeting. This commitment ensures compliance with insider trading regulations and maintains fair disclosure practices.

Schedule Flexibility

The company has noted that the meeting schedule remains subject to change due to any exigencies that may arise. This standard disclaimer provides operational flexibility while maintaining transparency with stakeholders about potential modifications to the planned timeline.

The disclosure was signed by Nagajayanthi J.R, Company Secretary & Compliance Officer, on March 16, 2026, demonstrating the company's commitment to timely regulatory reporting and investor communication.